Skip to content
Triangle logo TriangleGet started
← Prostate Cancer

HEALTH PROFESSIONAL · SOURCE READING

Hormone therapy with PARP inhibitors for men with mCRPC and BRCA1, BRCA2, or ATM variants

Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Recurrent Hormone-Sensitive or Hormone-Resistant Prostate Cancer / Treatment Options for Recurrent Prostate Cancer

Continue within this section

PARP inhibitors as first-line therapy for men with mCRPC and BRCA1 or BRCA2 variants →PARP inhibitors as first-line therapy for men with mCRPC and variants in homologous recombination repair genes →

Preserved source evidence · Not medical advice